Dermatology
Skin clinical trials
Psoriasis, eczema, skin cancers, and other conditions of the skin and connective tissue. We’re tracking 5,021 recruiting studies in this area right now.
By phase
- Not applicable2,807
- Phase 2752
- Phase 1522
- Phase 3382
- Phase 1/Phase 2294
- Phase 4205
- Phase 2/Phase 359
Top conditions
- Breast Cancer1,192
- Melanoma175
- Metastatic Breast Cancer138
- Rheumatoid Arthritis132
- Atopic Dermatitis125
- Systemic Lupus Erythematosus119
- Breast Neoplasms111
- Triple Negative Breast Cancer111
- Colorectal Cancer94
- Ovarian Cancer92
- Psoriasis85
- Breast Carcinoma79
- Lung Cancer77
- Prostate Cancer70
- Rheumatoid Arthritis (RA)68
- Diabetic Foot Ulcer59
- Cancer58
- Systemic Lupus Erythematosus (SLE)52
Leading sponsors
- Fudan University64
- M.D. Anderson Cancer Center51
- Novartis Pharmaceuticals49
- Memorial Sloan Kettering Cancer Center48
- Mayo Clinic40
- AstraZeneca38
- Assistance Publique - Hôpitaux de Paris37
- National Cancer Institute (NCI)37
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University35
- Second Affiliated Hospital, Zhejiang University, School of Medicine30
Where studies are running
- California406
- Arizona152
- Alabama129
- Florida126
- New York111
- Texas106
- Maryland95
- Massachusetts88
- Pennsylvania72
- North Carolina67
Recruiting studies5,021 total
- NCT06313463RecruitingPhase 3
Capecitabine and camrelizumab for TNBC after chemotherapy
This trial tests if combining the chemotherapy pill capecitabine with the immunotherapy drug camrelizumab can help people with triple-negative breast cancer (TNBC) who still have tumor tissue after initial treatment. It is for patients whose breast cancer has structures called tumor-associated lymphoid structures (TLS) and who did not achieve a complete response to neoadjuvant therapy.
Guangzhou, GuangdongAges 18–80 - NCT05280314RecruitingPhase 2
Immunotherapy before and after surgery for stage III melanoma or throat cancer
This trial tests two immunotherapy medicines given before surgery and again after surgery to help control the cancer and improve outcomes. It studies people with resectable (operable) stage III melanoma or certain stage III/IVA throat cancers.
New Haven, ConnecticutAges 18 years+ - NCT06315868Recruiting
Breast cancer organoid study for tumor analysis
This study is testing a new way to understand your breast cancer by growing tiny tumor samples (called organoids) in the lab. It will help researchers learn more about your cancer type and could lead to better treatments.
RomaAges 18–70 - NCT06227117RecruitingPhase 2
Study of DV and Toripalimab before surgery for HER2-low breast cancer
This trial tests a combination of two drugs (DV and Toripalimab) with chemotherapy before surgery for a specific type of breast cancer (HER2-low, HR-negative) that has not spread too far. The goal is to see if this approach can shrink the tumor and improve outcomes.
Changsha, HunanAges 18 years+ - NCT06319157Recruiting
Minimal access vs. standard back muscle flap for breast reconstruction
This study compares a less invasive method of harvesting the latissimus dorsi (a back muscle) for breast reconstruction. It is for early-stage breast cancer patients who have mild to moderate breast sagging and want to use their own tissue for reconstruction.
Guangzhou, GuangdongAges 18–70 - NCT06314906RecruitingPhase 3
Acupuncture plus anti-nausea drugs for breast cancer chemo side effects
This trial tests whether adding electroacupuncture (a type of acupuncture with mild electrical pulses) to standard anti-nausea medicine can better prevent nausea and vomiting caused by strong chemotherapy. It is for people with early-stage breast cancer who are about to start a very strong chemotherapy regimen.
Lanzhou, GansuAges 18–75 - NCT06321653Recruiting
Lymphedema after radiation for early breast cancer with 1-2 positive nodes
This trial aims to see if a shorter course of radiation after breast-conserving surgery affects arm swelling (lymphedema) in people with early breast cancer that has spread to 1 or 2 nearby lymph nodes. The goal is to learn if this approach is safe and effective.
MilanAges 18 years+ - NCT06265025RecruitingPhase 1/Phase 2
GM103 injection for advanced solid tumors that can't be removed
This trial tests an experimental drug called GM103 that is injected directly into tumors. It is for people with advanced solid tumors that have not responded to other treatments and cannot be surgically removed.
Goyang-si, Gyeonggi-doAges 18 years+ - NCT05861271RecruitingPhase 2
Adjuvant pyrotinib plus capecitabine for tiny HER2 breast cancer
This trial studies whether adding pyrotinib and capecitabine after surgery can lower the risk of cancer coming back in people with very small, lymph-node–negative, HER2-positive breast cancer. It’s for patients who fit specific tumor size and HER2 test results and who can safely take chemotherapy-like medicines and stay on contraception during treatment.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06330870Recruiting
How breast cancer spreads to the brain
This study looks at how breast cancer spreads to the brain in people who had surgery to remove brain tumors. It helps doctors understand why some women get brain metastases.
SeoulAges Any age - NCT06340516Recruiting
Looking at a blood test to track heart health during HER2 breast cancer treatment
This trial is checking if a simple blood test (NT-proBNP) can help spot early signs of heart side effects from certain breast cancer treatments (chemotherapy plus HER2 blockers). If successful, it might help doctors adjust treatment sooner to protect your heart.
GothenburgAges 18 years+ - NCT06341894RecruitingPhase 2
Dalpiciclib and hormone therapy for early breast cancer
This trial tests a new pill (dalpiciclib) combined with hormone therapy for women with early-stage, hormone receptor positive/HER2-negative breast cancer. The goal is to see if this combination can lower the chance of cancer coming back after surgery.
Nanjing, JiangsuAges 18–75 - NCT06334471Recruiting
Whole genome sequencing for breast cancer
This trial uses whole genome sequencing, a test that reads the complete set of your DNA, to study breast cancer tissue. This may help doctors learn more about the disease and find better treatments.
SeoulAges 19 years+ - NCT05761314Recruiting
Study treatments for cancers in people with RASopathy
This study looks at people who have a RASopathy—a genetic condition—and also have solid tumors (tumor growths not in blood). To join, your RASopathy must be confirmed by genetic testing, not only by symptoms.
RomaAges Any age - NCT06336070Recruiting
Power training for metabolic health in postmenopausal cancer survivors
This trial compares two types of exercise—muscle power training and metabolic power training—to see which better improves your body's ability to use energy and control heart function. You may qualify if you are a postmenopausal woman who has had breast cancer and is not currently active.
Valencia, ValenciaAges 35–75 - NCT05625633RecruitingPhase 2/Phase 3
HPV vaccine vs placebo for stubborn skin warts
This study tests whether an HPV vaccine can help shrink or clear cutaneous (skin) warts that have not responded to prior treatments. Participants get the study vaccine or a placebo to compare results and safety.
Salt Lake City, UtahAges 18 years+ - NCT05800132Recruiting
AI helps review routine breast mammograms for screening
This study tests whether an artificial intelligence (AI) system can help a second reader interpret routine breast screening mammograms. It may improve how consistently images are assessed, especially when the first reader calls them normal or benign.
AubagneAges 50–74 - NCT06341621RecruitingPhase 3
Skipping chemo for ER+/HER2- breast cancer with 1–3 positive nodes
This trial tests whether skipping chemotherapy is safe for women with a specific type of early-stage breast cancer (ER-positive, HER2-negative) that has spread to 1–3 lymph nodes. Instead of chemo, you would receive a targeted pill called abemaciclib after standard hormone therapy.
ShanghaiAges 18–80 - NCT06149130RecruitingPhase 2
Testing adebrelimab, dalpiciclib, and hormone therapy for advanced breast cancer
This trial tests a combination of a new immunotherapy drug (adebrelimab) with a targeted pill (dalpiciclib) and standard hormone therapy for women with advanced hormone receptor positive, HER2 negative breast cancer. It may help patients who have not yet had certain prior treatments, aiming to slow the cancer's growth.
Wuhan, HubeiAges 18–75 - NCT04603209Recruiting
Check-in registry for radiation during breast-conserving surgery
This registry study tracks people with early-stage, single-area breast cancer to understand outcomes when radiation is given during breast-conserving surgery. It may help doctors improve treatment planning for patients like you.
Santa Monica, CaliforniaAges 18 years+ - NCT02897700RecruitingPhase 1
Testing chemotherapy choices for early breast cancer after surgery
This Phase 1 study tests different chemotherapy approaches in people with breast cancer that has been surgically removed but is early stage. It aims to find a chemotherapy plan that’s safe and works well right after surgery.
Ganzhou, JiangxiAges 18 years+ - NCT05371353Recruiting
Study of how long HPV vaccine immunity lasts
This study checks how well the HPV (cancer-preventing) vaccine protection stays in your body over time. It may help confirm the vaccine’s “long-lasting” immune response and guide future vaccination confidence.
Yangchun, GuangdongAges 9–45 - NCT05692778Recruiting
Care program for people with diabetes and foot problems
This trial is testing an improved care approach for people with diabetes who have foot complications, delivered through primary care. It may help by organizing care more effectively and supporting better diabetes and foot management.
GothenburgAges 18 years+ - NCT04204837RecruitingPhase 2
Nivolumab for advanced skin squamous cell cancer
This trial studies nivolumab, an immune therapy, for skin squamous cell cancer that can’t be cured with surgery or radiation. It aims to see how well the treatment shrinks tumors and helps people live longer or longer without cancer growth.
GrazAges 18 years+
Common questions
- How many skin clinical trials are recruiting?
- Clin2 is tracking 5,021 recruiting dermatology studies from the U.S. registry right now, out of 7,720 we cover in this area in total.
- What does “Skin” cover here?
- Psoriasis, eczema, skin cancers, and other conditions of the skin and connective tissue. We group each study into skin based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a skin trial near me?
- Use the search to filter skin studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.